
Afonso Celso Vigorito

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7176399/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Expression of transforming growth factor \hat{I}^2 pathway components in chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Transplant Immunology, 2022, 70, 101514.	1.2	0
2	Oral shedding of CMV and HSVâ€1 in hematopoietic stem cell transplantation patients. Oral Diseases, 2021, 27, 1572-1579.	3.0	4
3	Hematopoietic cell transplantation in pediatric patients with acute leukemias or myelodysplastic syndrome using unrelated adult or umbilical cord blood donors in Brazil. Pediatric Transplantation, 2020, 24, e13789.	1.0	3
4	Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Graft- versus -host disease. Einstein (Sao Paulo, Brazil), 2020, 18, eAE4799.	0.7	5
5	Expression of Notch Pathway Components in Primary Samples of Allogeneic Hematopoietic Cell Transplant Patients with Chronic Graft Versus Host Disease. Blood, 2019, 134, 5600-5600.	1.4	0
6	Acute and chronic Graft-versus-host disease after hematopoietic stem cell transplantation. Revista Da Associação Médica Brasileira, 2016, 62, 44-50.	0.7	22
7	Pretransplant β 2 -Microglobulin Is Associated with the Risk of Acute Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplant. Biology of Blood and Marrow Transplantation, 2016, 22, 1329-1332.	2.0	2
8	Survival and graftâ€versusâ€host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from <scp>HLA</scp> â€matched related donor: retrospective analysis of 334 consecutive patients. European Journal of Haematology, 2015, 95, 421-425.	2.2	14
9	Pre-Transplant Beta2-Microglobulin Is an Independent Biomarker of Acute Graft-Versus-Host-Disease after Allogeneic Hematopoietic Cell Transplant in a Single Institutional Study. Blood, 2015, 126, 3152-3152.	1.4	0
10	Lack Of Advantage Of Peripheral Blood Hematopoietic Stem Cell Transplantation Over Bone Marrow From HLA Matched Related Donors After Myeloablative Conditioning For Hematologic Malignancies. Blood, 2013, 122, 5470-5470.	1.4	0
11	A High Angiopoietin-2/Angiopoietin-1 Ratio Independently Predicts Septic Shock Development in Patients with Chemotherapy-Associated Febrile Neutropenia and Hematological Malignancies Blood, 2012, 120, 2154-2154.	1.4	0
12	The Utilization of NET Promoter System As a Blood Supply Management Strategy. Blood, 2012, 120, 4378-4378.	1.4	0
13	Hematopoietic Cell Transplantation Co-Morbidity Index (HCT-CI) to Predict Non Relapse Mortality After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood, 2011, 118, 4561-4561.	1.4	2
14	Allogeneic Peripheral Blood Stem Cell Transplants (PBSCT) May Have a Benefit in Acute Lymphoblastic Leukemia (ALL) Outcome Blood, 2005, 106, 1136-1136.	1.4	0
15	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) - EBMT Risk Score Evaluation for Chronic Myeloid Leukemia in Brazil Blood, 2004, 104, 3334-3334.	1.4	Ο